Bioneer Corporation
Financials
Valuation Metrics
Bioneer Corporation's Market Cap is ₩2297B. At end of 2025 it was ₩3291B. Ranked #777 of 2,421 in KR market (top 32%), #350 of 1,640 on KOSDAQ (top 21%), #85 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 229.71B KRW | KR#777/2,421 Sec#85/231 |
| Revenue | 345.88B KRW | KR#775/2,421 Sec#35/231 |
| Net Income | -3.67B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 369.32B KRW | KR#915/2,421 Sec#56/231 |
| Net Assets | 217.58B KRW | KR#898/2,421 Sec#63/231 |
| Employees | 392 | KR#623/2,421 Sec#54/231 |
| Value | ||
| P/B | 1.06x | KR#1,513/2,421 Sec#95/231 |
| P/S | 0.66x | KR#1,111/2,421 Sec#52/231 |
| EV/EBITDA | 46.57x | KR#1,330/2,421 Sec#84/231 |
| FCF Yield | 1.54% | KR#1,096/2,421 Sec#76/231 |
| Profitability | ||
| ROE | -1.69% | KR#1,664/2,421 Sec#114/231 |
| ROA | -0.99% | KR#1,678/2,421 Sec#116/231 |
| Op. Margin | 1.80% | KR#1,412/2,421 Sec#98/231 |
| Revenue Growth | 15.87% | KR#659/2,421 Sec#61/231 |
| Financial Health | ||
| Debt Ratio | 69.74% | KR#1,216/2,421 Sec#148/231 |
| Total Debt | 104.64B KRW | KR#709/2,421 Sec#44/231 |
| FCF | 3.55B KRW | KR#988/2,421 Sec#71/231 |
| Cash | 43.98B KRW | KR#799/2,421 Sec#49/231 |
| Current Ratio | 2.00x | KR#870/2,421 Sec#98/231 |
| Net Debt/EBITDA | 9.73x | KR#1,212/2,421 Sec#88/231 |
| Dividend | ||
| Div. Yield | 4.09% | KR#408/2,421 Sec#14/231 |
| Performance | ||
| 1Y Return | -39.25% | KR#1,814/2,421 Sec#150/231 |
| 1M Return | -3.16% | KR#1,598/2,421 Sec#127/231 |
| From 52W High | -43.09% | KR#1,063/2,421 Sec#74/231 |
| 1Y MDD | -62.65% | KR#1,623/2,421 Sec#130/231 |
| Trading | ||
| Volume | 252,681 shares | KR#407/2,421 Sec#23/231 |
| Trading Value | 2.26B KRW | KR#530/2,421 Sec#49/231 |
| Foreign Own. | 4.42% | KR#964/2,421 Sec#84/231 |
| Per Share | ||
| EPS | -142 KRW | KR—/2,421 Sec—/231 |
| BPS | 8,430 KRW | KR#1,097/2,421 Sec#76/231 |
Company Info
Established in 1992 as the first researcher startup from the Korea Research Institute of Bioscience and Biotechnology, the company is a genetic engineering specialist listed on KOSDAQ in 2005. It operates diverse bio-healthcare businesses, including life science research equipment, reagents, molecular diagnostics, and synthetic biology. The company is developing a next-generation molecular diagnostics platform and a SAMiRNA new drug development platform to pursue global market entry. It also reinvests in research and development and expands its business portfolio through technological innovation. Bioneer is headquartered in Yuseong-gu, Daejeon.